CoLucid Pharmaceuticals (CLCD): Notes From KOL Call - Piper Jaffray

September 30, 2016 6:22 AM EDT
Get Alerts CLCD Hot Sheet
Price: $46.25 --0%

Rating Summary:
    4 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 22 | Down: 32 | New: 34
Trade CLCD Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on CoLucid Pharmaceuticals (NASDAQ: CLCD) and raised his price target to $49.00 from $36.00 after the analyst hosted an expert in the migraine space to discuss targeted treatments in clinical development, including CoLucid’s lasmiditan and CGRP antibodies.

The analyst raised his PT based on the potential of lasmiditan to generate long-term commercial value. Specifically, he thinks this may be driven by lasmiditan’s differentiated efficacy (with clinical benefit possibly under-estimated by the stringent Phase III endpoint), by its tolerability (with dizziness likely “worth it” for the modest % who experience it), and by its clean safety (which is likely to disrupt the SOC for migraine and expand the population receiving medical treatment).

Upcoming catalysts are SPARTAN and GLADIATOR progress this year, and top-line SPARTAN results expected in 3Q17,

For an analyst ratings summary and ratings history on CoLucid Pharmaceuticals click here. For more ratings news on CoLucid Pharmaceuticals click here.

Shares of CoLucid Pharmaceuticals closed at $34.74 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Management Comments

Related Entities

Piper Jaffray, Charles Duncan

Add Your Comment